Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Sensei Biotherapeutics (SNSE)

Sensei Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SNSE
DateTimeSourceHeadlineSymbolCompany
13/06/202422:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
13/06/202422:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
13/06/202422:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
13/06/202422:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
13/06/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
13/06/202421:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
03/06/202412:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
23/05/202422:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
09/05/202421:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNSESensei Biotherapeutics Inc
09/05/202412:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
05/03/202421:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
28/02/202412:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
16/02/202423:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
16/02/202423:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
16/02/202423:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
08/02/202421:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
04/01/202413:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
07/11/202321:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNSESensei Biotherapeutics Inc
07/11/202312:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
07/11/202312:30GlobeNewswire Inc.Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:SNSESensei Biotherapeutics Inc
06/11/202311:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
03/11/202320:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
03/11/202320:05GlobeNewswire Inc.Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual MeetingNASDAQ:SNSESensei Biotherapeutics Inc
02/11/202320:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
02/11/202320:50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
01/11/202311:30GlobeNewswire Inc.Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business OfficerNASDAQ:SNSESensei Biotherapeutics Inc
25/10/202314:05GlobeNewswire Inc.Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual MeetingNASDAQ:SNSESensei Biotherapeutics Inc
23/10/202312:30GlobeNewswire Inc.Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023NASDAQ:SNSESensei Biotherapeutics Inc
20/10/202322:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
27/09/202312:30GlobeNewswire Inc.Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®NASDAQ:SNSESensei Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SNSE

Your Recent History

Delayed Upgrade Clock